← Leaderboards
Ken M. Kunisaki
University Of Minnesota
$6,591,253
Attributed
$10,165,956
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,165,956 · 4
By mechanism
R01$10,165,956 · 4
Top collaborators
- Susan S Redline5 shared
- Timothy J. Griffin4 shared
- Chris H Wendt4 shared
- Kristina Anne Crothers1 shared
- Orly Vardeny1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Dickson Ally Mkoka$2,627,641
- Kristen Patricia Mark$1,522,697
- Shweta Sharma$1,014,507
- Birgit Grund$1,014,507
- Sebalda Leshabari$819,028
Others in their field
Top investigators on “Persons”
- Wafaa M. El-Sadr · Columbia University Health Sciences$688,439,560
- Lawrence Corey · Fred Hutchinson Cancer Center$646,462,796
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- David R. Weir · University Of Michigan At Ann Arbor$386,183,647
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$377,922,183
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$265,384,316
Research focus
PersonsParticipantReportingPublic Health RelevanceAntiretroviral TherapyLungSmoking StatusPathogenesisRepositoryDesignLung DiseasesQuestionnairesFutureEnrollmentAnti-Retroviral AgentsChronic Obstructive Airway DiseaseAffectChronicHiv InfectionsBiologicalRespiratory PhysiologyDisorder RiskComorbidityProteomics
Grant awards (18)
Optimizing Medications and Lung Health in People with HIV through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)$803,801
R01 · FY2025 · HL
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$667,118
R01 · FY2021 · HL
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$667,118
R01 · FY2020 · HL
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$671,673
R01 · FY2019 · HL
Sleep, Aging, and HIV Infection Cohort Study$531,642
R01 · FY2019 · HL · contact PI
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease$743,025
R01 · FY2018 · HL
Sleep, Aging, and HIV Infection Cohort Study$616,288
R01 · FY2018 · HL · contact PI
Sleep, Aging, and HIV Infection Cohort Study$567,990
R01 · FY2017 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmonary function in a randomized trial$282,918
R01 · FY2017 · HL · contact PI
Sleep, Aging, and HIV Infection Cohort Study$69,461
R01 · FY2017 · HL · contact PI
Sleep, Aging, and HIV Infection Cohort Study$627,046
R01 · FY2016 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmonary function in a randomized trial$533,374
R01 · FY2016 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmonary function in a randomized trial$679,523
R01 · FY2015 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmomary function in a randomized trial$518,747
R01 · FY2014 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmomary function in a randomized trial$503,931
R01 · FY2013 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmomary function in a randomized trial$552,353
R01 · FY2011 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmomary function in a randomized trial$515,991
R01 · FY2010 · HL · contact PI
Effects of HIV antiretroviral therapy on pulmomary function in a randomized trial$613,957
R01 · FY2009 · HL · contact PI